Describing Adverse Events Associated with Bilateral Same-Day Intravitreal Dexamethasone Implants.

Background and Objectives: To explore the incidence of adverse events after bilateral same-day intravitreal 0.7-mg dexamethasone implant (SDIDI) injections.
Materials and Methods: We performed an IRB approved, single-center, retrospective review of patients receiving bilateral SDIDI injections from January 1, 2016 to October 31, 2021 and reviewed adverse events that occurred within 3 months of injection.
Results: A total of 206 bilateral (412 eyes) SDIDI injections were performed in 59 patients. Ocular hypertension or the addition of intraocular pressure (IOP) lowering drops occurred in 121 (29.4%) eyes after IDI. Two (0.5%) eyes required glaucoma drainage surgeries. Of the 117 phakic eyes, 32 (27.4%) had progression of cataract or cataract extraction. There were two (0.5%) episodes of vitreous hemorrhage and one (0.2%) retinal tear with retinal detachment. There were no cases of endophthalmitis.
Conclusion: Serious complication rates after bilateral same-day IDI injections appears low. Increased IOP that requires intervention can occur. [ Ophthalmic Surg Lasers Imaging Retina 2022;53:612-618.] .